Disclosures for "Design and Baseline characteristic of Phase II clinical trial of allogeneic bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease")
-
Dr. Schiess has nothing to disclose.
-
The institution of Prof. Ellmore has received research support from NIMH.
-
The institution of Dr. Shahnawaz has received research support from American Parkinson Disease Association. The institution of Dr. Shahnawaz has received research support from NIH. The institution of Dr. Shahnawaz has received research support from Texas Alzheimer's Research & Care Consortium . Dr. Shahnawaz has received intellectual property interests from a discovery or technology relating to health care.
-
Marie-Francoise Doursout has nothing to disclose.
-
Dr. Adams has stock in Medtronic.
-
Dr. Tharp has nothing to disclose.
-
Jessika Suescun, MD has nothing to disclose.